pcn poster

Posters

More than Skin Deep: Examining the Full Impact of Tardive Dyskinesia

Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonists–most commonly antip...

08/20/2024

Multidimensional Impact of Tardive Dyskinesia: Interim Analysis of Clinician-Reported Measures in the IMPACT-TD Registry

Abstract: Background: The IMPACT-TD scale is a newly developed clinical tool to assess the multidimensional impact of tardive dyskinesia (TD) on patients’ quality of life (QoL). Methods: ...

08/20/2024

Obligate Mirror Alternating Hemi-auto-prosopometamorphopsia of Kith and Kin

Abstract: Introduction: Obligate mirror alternating hemiprosopometamorphopsia has not heretofore been described. Such a case is presented. Methods: Case Report: A 37 year old right hand...

08/20/2024

Patient-reported depressive symptoms among individuals diagnosed with Major Depressive Disorder with and without prominent anhedonia using a real-world dataset

Abstract: Anhedonia is a core feature of major depressive disorder (MDD). However, little is known about its related symptom burden and its impact on patients’ clinical trajectory. This r...

08/20/2024

Pharmacokinetics and Safety of LY03010, a Novel Monthly Intramuscular Injectable Extended-release Paliperidone Palmitate Suspension in Patients with Schizophrenia or Schizoaffective Disorder

Abstract: LY03010 (paliperidone palmitate) is in development as a pharmaceutical equivalent drug product to the listed drug (LD), INVEGA SUSTENNA® for schizophrenia and schizoaffective di...

08/20/2024

Polypharmacy and deprescribing of cholinesterase inhibitors in dementia: a case report and literature review

Abstract: The patient is an 81-year-old female with a past medical history of dementia who presented to the hospital for a mechanical fall. Her medication reconciliation revealed she had ...

08/20/2024

Long-Term Efficacy of Esketamine Nasal Spray Among Early and Delayed Responders: A Subgroup Analysis of the SUSTAIN-3 Study

Abstract: Objective: To describe the long-term efficacy of esketamine nasal spray (ESK) in adult patients (aged 18-64 years) with treatment-resistant depression (TRD) dosed according to U...

08/20/2024

Preliminary data from the CONNEX-X extension trial examining the long-term safety of iclepertin (BI 425809) in patients with schizophrenia who completed Phase III CONNEX trials

Abstract: Introduction: Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has improved cognitive impairment associated with schizophrenia (CIAS) in Phase II trials, with Phase II...

08/20/2024

Long-Term Safety and Efficacy of Esketamine Nasal Spray by Dosing Frequency in Adults With Treatment-Resistant Depression: Analysis of the SUSTAIN-3 Study

Abstract: Objective: To describe the long-term safety and efficacy of flexibly dosed esketamine nasal spray (ESK) in patients with treatment-resistant depression (TRD) from SUSTAIN-3 (NCT...

08/20/2024

Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder

Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real...

08/20/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products